Showing 1 to 1 of 1 results
forbes.com
🌐 75% Global Worthiness
HIMS Stock Surges 23% on Wegovy Partnership
Hims & Hers Health (HIMS) stock surged 23% on April 29th after Novo Nordisk announced it would offer its weight-loss drug Wegovy through HIMS's platform, significantly boosting HIMS's revenue potential due to its large subscriber base and the high price of Wegovy.
HIMS Stock Surges 23% on Wegovy Partnership
Hims & Hers Health (HIMS) stock surged 23% on April 29th after Novo Nordisk announced it would offer its weight-loss drug Wegovy through HIMS's platform, significantly boosting HIMS's revenue potential due to its large subscriber base and the high price of Wegovy.
Progress
48% Bias Score
Good Health and Well-being
Showing 1 to 1 of 1 results